4. Investment Case review process
4.1 Approved the proposed investment case review process including the creation of an independent review group to provide recommendations to the GAVI Board for decision.
4.2 Agreed to review the proposed review committee members and respond to the Secretariat by email within one week (by 6 May), but requested additional information concerning the reasons why these particular individuals are being proposed.
4.3 Agreed that the investment cases dependent on IFFIm funding – measles, maternal and neonatal tetanus, and polio stockpile – should be presented to the Board for decision in July, considering the need to disburse funding quickly should the IFFIm be launched at the G8 Summit in early July.
4.4 Agreed that new vaccine investment cases should not be submitted in December 2005 but delayed to allow for more time for high-level strategic discussions. Further, the Board will need to judge the vaccine investment cases against the proportion of overall resource envelope.
4.5 Requested the Working Group to explore the issues relating to the process for solicitation of vaccine investment cases, and submit its recommendations to the GAVI Board at a future meeting.